Cite
HARVARD Citation
Clark, L. et al. (2017). Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease. Journal of medical economics. pp. 715-722. [Online].